Benralizumab in severe eosinophilic asthma

Background: Severe asthma is a significant cause of morbidity, and biologic therapies may offer benefits for some patients. Benralizumab, a monoclonal antibody, targets the interleukin-5 receptor (IL-5R) on eosinophils, preventing IL-5 from binding to its receptor. This action inhibits the differentiation and maturation of eosinophils in the bone marrow, making benralizumab a promising treatment for severe eosinophilic asthma. Following its marketing approval in Turkey in October 2023, this study aims to share initial clinical experience with benralizumab in treating severe eosinophilic asthma. Methods: A retrospective review was conducted on the medical records of 30 adult patients diagnosed with severe eosinophilic asthma, including both biologic-naive patients and those previously treated with biologics. These patients were initiated on benralizumab between 01 November 2023 and 01 October 2024, and their clinical data, including asthma control test scores, St. George’s Respiratory Questionnaire scores, eosinophil counts, pulmonary function forced expiratory volume 1, frequency of asthma attacks, and oral corticosteroid use, were collected before and after benralizumab initiation. Results: We observed that despite the presence of comorbidities, significant clinical improvements were observed within four weeks of starting benralizumab, with measurable effects as early as one month. Conclusions: Benralizumab based recoveries were consistent across multiple outcome measures, including asthma control, quality of life, and pulmonary function.

Severe eosinophilic asthma; Benralizumab; Quality of life; Asthma attacks; FEV1

[1] Sim S, Choi Y, Park HS. Update on inflammatory biomarkers for defining asthma phenotype. Allergy, Asthma & Immunology Research. 2024; 16: 462–472.

[2] Lavoie G, Pavord ID. Biologics in asthma: role of biomarkers. Immunology and Allergy Clinics of North America. 2024; 44: 709–723.

[3] Bourdin A, Brusselle G, Couillard S, Fajt ML, Heaney LG, Israel E, et al. Phenotyping of severe asthma in the era of broad-acting anti-asthma biologics. The Journal of Allergy and Clinical Immunology: In Practice. 2024; 12: 809–823.

[4] Global Initiative for Asthma. 2024 severe asthma guide. 2024. Available at: https://ginasthma.org/severe-asthma/ (Accessed: 07 May 2024).

[5] Pagani M, Bavbek S, Alvarez-Cuesta E, Berna Dursun A, Bonadonna P, Castells M, et al. Hypersensitivity reactions to chemotherapy: an EAACI position paper. Allergy. 2022; 77: 388–403.

[6] Yildiz F, Mungan D, Gemicioglu B, Yorgancioglu A, Dursun B, Oner Erkekol F, et al. Asthma phenotypes in Turkey: a multicenter cross-sectional study in adult asthmatics; PHENOTURK study. The Clinical Respiratory Journal. 2017; 11: 210–223.

[7] Jackson DJ, Wechsler ME, Brusselle G, Buhl R. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of anti-IL-5 versus anti-IL-5 receptor agents. Allergy. 2024; 79: 2943–2952.

[8] Chan R, RuiWen Kuo C, Jabbal S, Lipworth BJ. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma. Journal of Allergy and Clinical Immunology. 2023; 151: 700–705.

[9] Vitale C, Maglio A, Pelaia C, D’Amato M, Ciampo L, Pelaia G, et al. Effectiveness of benralizumab in OCS-dependent severe asthma: the impact of 2 years of therapy in a real-life setting. Journal of Clinical Medicine. 2023; 12: 985.

[10] Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, et al. Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme. European Respiratory Journal. 2024; 64: 2301521.

[11] Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of ben ralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and lo ng-acting â2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. The Lancet. 2016; 388: 2115–21227.

[12] FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2016; 388: 2128–2141.

[13] Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. The New England Journal of Medicine. 2017; 376: 2448–2458.

[14] Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. The Lancet Respiratory Medicine. 2019; 7: 46–59.

[15] Soong W, Chipps BE, Carr W, Trevor J, Patel A, Clarke N, et al. Quality of Life improvements with biologic initiation among subspecialist-treated us patients with severe asthma. Journal of Asthma and Allergy. 2024; 17: 441–448.

[16] Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respiratory Medicine. 1991; 85: 25–31; discussion 33–37.

[17] Ferrer M, Alonso J, Prieto L, Plaza V, Monsó E, Marrades R, et al. Validity and reliability of the St George’s Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. European Respiratory Journal. 1996; 9: 1160–1166.

[18] FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. The Lancet Respiratory Medicine. 2018; 6: 51–64.

[19] Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies. Current Medical Research and Opinion. 2017; 33: 1605–1613.

[20] Bleecker ER, Wechsler ME, FitzGerald JM, Menzies-Gow A, Wu Y, Hirsch I, et al. Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. European Respiratory Journal. 2018; 52: 1800936.

[21] O’Quinn S, Xu X, Hirsch I. Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma. Journal of Asthma and Allergy. 2019; 12: 21–33.

[22] Padilla-Galo A, Levy-Abitbol R, Olveira C, Valencia Azcona B, Pérez Morales M, Rivas-Ruiz F, et al. Real-life experience with benralizumab during 6 months. BMC Pulmonary Medicine. 2020; 20: 184.

[23] Paçacı Çetin G, Kepil Özdemir S, Can Bostan Ö, Öztop N, Çelebi Sözener Z, Karakaya G, et al. Biologics for the treatment of severe asthma: current status report 2023. Tuberculosis and Thorax. 2023; 71: 176–187. (In Turkish)

[24] Watanabe H, Shirai T, Hirai K, Akamatsu T, Nakayasu H, Tamura K, et al. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients. Journal of Asthma. 2022; 59: 1796–1804.

[25] Kearney CM, Sangani R, Shankar D, O’Connor GT, Law AC, Walkey AJ, et al. Comparative effectiveness of mepolizumab, benralizumab, and dupilumab among patients with difficult-to-control asthma: a multicenter retrospective propensity-matched analysis. Annals of the American Thoracic Society. 2024; 21: 866–874.

[26] Yamada H, Nakajima M, Matsuyama M, Morishima Y, Arai N, Hida N, et al. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma. PLOS ONE. 2021; 16: e0248305.

[27] Tepetam FM, Akyildiz AB, Özden Ş, Örcen C, Yakut T, Atik Ö. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic “Overlap” severe asthma: biological agent preference in atopic-eosinophilic severe asthma. Medicine. 2023; 102: e33660.

[28] Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Annals of Allergy, Asthma & Immunology. 2018; 120: 504–511.e4.

[29] Farne HA, Wilson A, Milan S, Banchoff E, Yang F, Powell CV. Anti-IL-5 therapies for asthma. Cochrane Database of Systematic Reviews. 2022; 7: CD010834.

[30] Jackson DJ, Korn S, Mathur SK, Barker P, Meka VG, Martin UJ, et al. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Safety. 2020; 43: 409–425.

[31] Pelaia C, Crimi C, Benfante A, Caiaffa MF, Calabrese C, Carpagnano GE, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. Journal of Asthma and Allergy. 2021; 14: 163–173.

[32] Dhariwal J, Hearn AP, Kavanagh JE, d’Ancona G, Green L, Fernandes M, et al. Real-world effectiveness of anti-IL-5/5R therapy in severe atopic eosinophilic asthma with fungal sensitization. The Journal of Allergy and Clinical Immunology: In Practice. 2021; 9: 2315–2320.e1.

[33] Liu MC, Chipps B, Munoz X, Devouassoux G, Bergna M, Smith SG, et al. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. Respiratory Research. 2021; 22: 144.